Theratechnologies (TSE:TH) Stock Price Crosses Below 50-Day Moving Average of $4.05

Theratechnologies Inc. (TSE:TH) passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of C$4.05 and traded as low as C$3.50. Theratechnologies shares last traded at C$3.63, with a volume of 21,764 shares changing hands.

Separately, National Bankshares reaffirmed a “hold” rating and set a C$3.75 price target on shares of Theratechnologies in a research report on Thursday, October 14th.

The firm’s 50 day moving average price is C$4.05 and its 200-day moving average price is C$4.34. The company has a debt-to-equity ratio of 210.06, a quick ratio of 1.48 and a current ratio of 2.22. The firm has a market capitalization of C$345.29 million and a PE ratio of -9.26.

Theratechnologies (TSE:TH) last posted its earnings results on Wednesday, October 13th. The company reported C($0.12) earnings per share (EPS) for the quarter. The firm had revenue of C$22.22 million for the quarter. On average, equities research analysts expect that Theratechnologies Inc. will post -0.1314444 earnings per share for the current fiscal year.

In related news, Director Dale Weil purchased 11,470 shares of the firm’s stock in a transaction that occurred on Monday, October 25th. The shares were purchased at an average cost of C$4.39 per share, with a total value of C$50,353.30. Following the purchase, the director now owns 28,170 shares of the company’s stock, valued at approximately C$123,666.30.

Theratechnologies Company Profile (TSE:TH)

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients.

Further Reading: Are sell-side analysts objective?

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with's FREE daily email newsletter.